Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer

• Main Authors: Vicenç Ruiz de Porras (Author), Adrià Bernat-Peguera (Author), Clara Alcon (Author), Fernando Laguia (Author), Maria Fernández-Saorin (Author), Natalia Jiménez (Author), Ana Senan-Salinas (Author), Carme Solé-Blanch (Author), Andrea Feu (Author), Mercedes Marín-Aguilera (Author), Juan Carlos Pardo (Author), Maria Ochoa- (Author), Joan Montero (Author), Begoña Mellado (Author), Albert Font (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Docetaxel remains the standard treatment for metastatic castration-resistant prostate cancer (mCRPC). However, resistance frequently emerges as a result of hyperactivation of the PI3K/AKT and the MEK/ERK pathways. Therefore, the inhibition of these pathways presents a potential therapeut...